Kevin Koch - May 1, 2024 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Role
President and CEO, Director
Signature
/s/John R. Moore Attorney-in-Fact for Kevin Koch
Stock symbol
EWTX
Transactions as of
May 1, 2024
Transactions value $
-$59,604
Form type
4
Date filed
5/3/2024, 06:26 PM
Previous filing
Aug 18, 2023
Next filing
Aug 14, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EWTX Common Stock Options Exercise $0 +10.4K +144.42% $0.00 17.6K May 1, 2024 Direct
transaction EWTX Common Stock Sale -$59.6K -3.15K -17.88% $18.91 14.5K May 2, 2024 Direct F1, F2
holding EWTX Common Stock 260K May 1, 2024 See Footnotes F3
holding EWTX Common Stock 26.4K May 1, 2024 See Footnotes F4
holding EWTX Common Stock 26.4K May 1, 2024 See Footnotes F5
holding EWTX Common Stock 26.4K May 1, 2024 See Footnotes F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EWTX Restricted Stock Units Options Exercise $0 -10.4K -50% $0.00 10.4K May 1, 2024 Common Stock 10.4K $0.00 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person
F2 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.68 to $19.12, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 These shares are held directly by the KTK Family Enterprise, LLC for the which the Reporting Person serves as Manager.
F4 These shares are held directly by the Adrienne R. Koch Heritage Trust for which the Reporting Person and his spouse serve as co-trustees.
F5 These shares are held directly by the Matthew K. Koch Heritage Trust for which the Reporting Person and his spouse serve as co-trustees.
F6 These shares are held directly by the Nicole M. Soldow Heritage Trust for which the Reporting Person and his spouse serve as co-trustees.
F7 RSUs granted to the reporting person which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023.